TTRX Turn Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2023016 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-236.5%
TTM EPS YoY-186.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-412.3%
ROA-123.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets65.2%
Debt / equity1.09x
Current ratio3.19x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.41x
Accruals ratio-72.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $265,570 | $245,956 |
| SG&A expense | $5.59M | $1.55M |
| Operating income | -$5.86M | -$1.80M |
| Net income | -$3.19M | -$1.77M |
| EBITDA | -$5.81M | -$1.75M |
| EPS (basic) | -0.12 | -0.07 |
| EPS (diluted) | -0.12 | -0.07 |
| Weighted avg. shares (diluted) | 27.72M | 26.64M |
| Balance sheet | ||
| Cash & equivalents | $4.03M | $872,599 |
| Current assets | $5.20M | $1.10M |
| Intangibles | $922,171 | $821,931 |
| Total assets | $12.16M | $2.05M |
| Current liabilities | $6.00M | $707,932 |
| Total liabilities | $7.48M | $2.23M |
| Shareholders' equity | $4.69M | -$177,432 |
| Shares outstanding | 29.45M | 26.85M |
| Cash flow statement | ||
| Operating cash flow | -$2.56M | -$1.36M |
| Investing cash flow | -$152,986 | -$99,475 |
| Financing cash flow | $6.92M | $1.15M |
| Depreciation & amortization | $52,746 | $47,483 |
| Stock-based compensation | $419,245 | $352,833 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.